Advertisement

Topics

Obsidian Therapeutics, Inc. Company Profile

13:00 EDT 19th July 2018 | BioPortfolio

Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing domains by Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian’s lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy. Obsidian was founded in 2015 by Atlas Venture and is funded by a strong syndicate of venture investors. The company is headquartered in Cambridge, Massachusetts. Please visit www.obsidiantx.com.


News Articles [783 Associated News Articles listed on BioPortfolio]

Obsidian Therapeutics to Present at Upcoming Investor Conferences

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced ...

Obsidian Energy Announces Legacy Asset Disposition

David French, President & CEO commented, "This transaction is another important step forward for Obsidian Energy. It demonstrates the continued refocusing of the business only Read more...

Obsidian Energy: FrontFour is Risking the Company's Progress

Jay Thornton, Chairman of the Obsidian Energy Board of Directors (the " Board"), commented, "We are disappointed that after several months of attempting Read more...

Obsidian Energy Comments on Statement by FrontFour Capital Group LLC

Obsidian Energy's corporate strategy is well defined and has the unanimous support of the Board of Directors (the "Board"). We have been organically growing the Read more...

Obsidian Energy Announces Strategic Actions to Unlock Shareholder Value

The Company is also announcing a deferral of the proposed share consolidation and changes to Obsidian Energy's Director compensation to further align director pay with Read more...

FrontFour Formally Provides Advance Notice of the Nomination of Four Highly Qualified Directors ...

FrontFour has also issued the following open letter to Obsidian shareholders: A LETTER TO THE SHAREHOLDERS OF OBSIDIAN ENERGY LTD. April 3, 2018 Dear Fellow Read more...

Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced ...

Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced ...

PubMed Articles [444 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [146 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1244 Associated Companies listed on BioPortfolio]

Obsidian Therapeutics, Inc.

Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing...

Obsidian Strategics

Obsidian Strategics™ is the developer of Longbow™, a series of InfiniBand products featuring range extension, routing and encryption. Longbow technology allows an Infini...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Obsidian Therapeutics, Inc." on BioPortfolio

We have published hundreds of Obsidian Therapeutics, Inc. news stories on BioPortfolio along with dozens of Obsidian Therapeutics, Inc. Clinical Trials and PubMed Articles about Obsidian Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Obsidian Therapeutics, Inc. Companies in our database. You can also find out about relevant Obsidian Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record